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ABSTRACT
Purpose. B-Raf
V600E may play a role in the progression
frompapillarythyroidcancertoanaplasticthyroidcan-
cer (ATC). We tested the effects of a highly selective
B-Raf
V600E inhibitor, PLX4720, on proliferation, migra-
tion, and invasion both in human thyroid cancer cell lines
(8505c
B-RafV600EandTPC-1
RET/PTC-1 and wild-type B-Raf)and
in primary human normal thyroid (NT) follicular cells
engineered with or without B-Raf
V600E.
ExperimentalDesign.Large-scalegenotypinganalysis
by mass spectrometry was performed in order to ana-
lyze>900genemutations.Cellproliferationandmigra-
tion/invasionwereperformeduponPLX4720treatment
in 8505c, TPC-1, and NT cells. Orthotopic implantation
of either 8505c or TPC-1 cells into the thyroid of severe
combined immunodeficient mice was performed. Gene
validations were performed by quantitative polymerase
chain reaction and immunohistochemistry.
Results. We found that PLX4720 reduced in vitro cell
proliferation and migration and invasion of 8505c cells,
causing early downregulation of genes involved in tu-
mor progression. PLX4720-treated NT cells overex-
pressing B-Raf
V600E (heterozygous wild-type B-Raf/
Correspondence: Sareh Parangi, M.D., Harvard Medical School, Massachusetts General Hospital, Unit of Endocrine Surgery, Wang
ACC 460, 15 Parkman Street, Boston, Massachusetts 02115, USA. Telephone: 617-643-4806; Fax: 617-643-4802; e-mail:
sparangi@partners.org Received September 19, 2010; accepted for publication January 20, 2011; first published online in The Oncol-
ogistExpressonFebruary25,2011;availableonlinewithoutsubscriptionthroughtheopenaccessoption.©AlphaMedPress1083-7159/
2011/$30.00/0 doi: 10.1634/theoncologist.2010-0317
The Oncologist
®
Endocrinology
The Oncologist 2011;16:296–309 www.TheOncologist.comB-Raf
V600E) showed significantly lower cell prolifera-
tion, migration, and invasion. PLX4720 treatment did
not block cell invasion in TPC-1 cells with wild-type B-
Raf, which showed very low and delayed in vivo tu-
mor growth. In vivo, PLX4720 treatment of 8505c
orthotopic thyroid tumors inhibited tumor aggres-
sivenessandsignificantlyupregulatedthethyroiddif-
ferentiation markers thyroid transcription factor 1
and paired box gene 8.
Conclusions. Here, we have shown that PLX4720
preferentially inhibits migration and invasion of
B-Raf
V600E thyroid cancer cells and tumor aggressive-
ness. Normal thyroid cells were generated to be
heterozygous for wild-type B-Raf/B-Raf
V600E, mimick-
ing the condition found in most human thyroid cancers.
PLX4720 was effective in reducing cell proliferation,
migration, and invasion in this heterozygous model.
PLX4720 therapy should be tested and considered for a
phase I study for the treatment of patients with
B-Raf
V600E ATC. The Oncologist 2011;16:296–309
INTRODUCTION
The incidence of well-differentiated thyroid cancers has
been increasing [1]. The majority of patients with these tu-
mors have a low risk for recurrence or death with standard
therapy (surgery, radioiodine, and thyroid-stimulating hor-
mone [TSH] suppression). However, a subset of patients
with aggressive thyroid cancer, especially anaplastic thy-
roid carcinoma (ATC), present with locally advanced dis-
ease that recurs and metastasizes [2]. Mutations in key
regulatory genes are likely to play an important role. Muta-
tions known to be important in papillary thyroid cancers
(PTCs) include: RET/PTC translocation (10%–50% of
PTCs) [3, 4], Ras mutations (about 12% of PTCs) [5], and
B-Raf
V600E mutations (29%–83% of PTCs) [6, 7].
B-Raf
V600Eisthesecondmostcommonsomaticmutationin
human cancer, with a frequency of approximately 8% [8].
TheB-Raf
V600Eprotein(valine-to-glutamate,position600)
resultsfromatransversioninthegene(T1799A)andresults
in increased mitogen-activated protein kinase (e.g., mito-
gen-activated protein kinase/extracellular signal–related
kinase kinase [MEK]-1/MEK-2, extracellular signal–re-
lated kinase [ERK]-1/ERK-2) activity [8, 12]. When PTC
and ATC occur together in the same thyroid malignant le-
sion, they generally share the B-Raf
V600E mutation, imply-
ing that many ATCs are derived from malignant
degeneration of pre-existing well-differentiated PTCs [13].
Ourstudyfocusesonfurtherelucidatingtheroleofthismu-
tation in aggressive thyroid cancers.
PLX4720 (7-azaindole derivative) is a selective small
molecule inhibitor of B-Raf
V600E [14]. PLX4720 was de-
signed to block the ATP-binding site of oncogenic
B-Raf
V600E [14]. PLX4720 binds selectively to the active
B-Raf
V600E protein conformation. Consistent with the high
degree of selectivity, PLX4720 inhibits B-Raf
V600E kinase
activity both in vitro and in vivo in melanoma and colorec-
tal tumor cell models [14].
We performed in vitro testing of PLX4720 on human thy-
roidcancercelllinesharboringtheB-Raf
V600Emutationorthe
RET/PTC-1 translocation (with wild-type [wt] B-Raf in both
alleles) and on primary human normal thyroid (NT) follicular
cells engineered to express B-Raf
V600E. We furthermore used
an orthotopic mouse model of ATC harboring B-Raf
V600E to
testindetailtheinvivoactivityofPLX4720ontumoraggres-
siveness using an early intervention model.
MATERIALS AND METHODS
Antibodies
Antibodies for Western blot (WB) and immunohistochem-
istry (IHC) are reported in the supplemental online data.
PLX4720 Preparation
PLX4720wasdissolvedindimethylsulfoxide(DMSO)at1
Mo r1 0M for in vitro assays. For the in vivo prepara-
tion, PLX4720 was dissolved in DMSO (120 mg/ml) and
then suspended in a 1% solution of carboxymethycellulose
(Sigma, St. Louis).
Human Thyroid Cancer Cell Lines and NT Cells
We used the TPC-1 cell line (human PTC, RET/PTC-1/wt for
B-Raf), provided by Dr. F. Frasca (University of Catania, Ca-
tania, Italy), and the 8505c cell line (human ATC harboring
B-Raf
V600E), purchased from DSMZ (German collection of
microorganismsandcellculture)[15].NTcellswereobtained
according to Fischer et al. [16]. All in vitro assays were per-
formed by growing these cell lines with the specific growth
medium supplemented with 1% fetal bovine serum. More de-
tails are reported in the supplemental online data.
Cell Transfections for Retrovirus Production
Sixty-millimeter plates of HEK 293T cells (5  10
5) were
transfected using Fugene-6 (Roche, Indianapolis) in Op-
tiMEM (Invitrogen, Carlsbad, CA) for 48 hours.
B-Raf
V600E Transduction in NT Cells
B-Raf
V600E-pBABE-puro and pBABE-puro (empty vector)
retroviral constructs were provided by Dr. W.C. Hahn (Dana
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MA) [17] and used for B-Raf
V600E overexpression (transduc-
tion) studies in NT cells (passage 0). For analysis, cells were
pelleted then processed according to Nucera et al. [18]. More
details are reported in the supplemental online data.
WB Analysis
WB assays and band densitometry were performed accord-
ing to a standard procedure [19].
Cell Cycle Analysis, Bromodeoxyuridine Assay,
and Apoptosis Assay
8505c, TPC-1, and NT cells were seeded at 3  10
5 cells/
10-cm dish. After 72 hours of treatment with PLX4720 (1
Mo r1 0M) or vehicle, bromodeoxyuridine (BrdU, 10
M) (Upstate Cell Signaling Solutions, Temecula, CA)
was added for 1 hour. The cell cycle analysis, BrdU assay,
and apoptosis assay were performed in triplicate according
to Nucera et al. [19].
Migration and Invasion Assays
Migration and invasion assays were performed in triplicate
using 8505c cells (8  10
3 cells/assay), TPC-1 cells (8 
10
3 cells/assay), and NT cells (25  10
3 cells/assay) for 72
hours in culture. More details are reported in the supple-
mental online data.
Quantitative Multigene Profiling by Real-Time
Reverse Transcriptase Polymerase Chain
Reaction Analysis
Quantitative multigene and absolute real-time reverse tran-
scriptase polymerase chain reaction (RT-PCR) were per-
formed according to Shih and Smith [20] (supplemental
online data and supplemental online Table 1).
Tumor Implantation
Animal work was performed in the animal facility at
Massachusetts General Hospital (Boston, MA) in accor-
dance with federal, local, and institutional guidelines.
Orthotopic thyroid tumor implantation was done as pre-
viously described in severe combined immunodeficient
(SCID) mice (Charles River Laboratories, Wilmington,
MA) using 8505c cells (5  10
5) engineered with green
fluorescent protein (GFP) [21] or TPC-1 cells (1  10
6).
Given our early-intervention design, 1 week post–tumor
implantation mice were treated with either PLX4720 (30
mg/kg per day, n  8) by oral gavage (Plexxikon, Berke-
ley, CA) or vehicle (n  8) once daily for 21 days.
Weight was recorded weekly.
Tumor burden was evaluated weekly by palpation, and
miceunderwentnecropsy35daysaftertumorimplantation.
Tumor size was measured using an electronic caliper. Tu-
mor volume was calculated as (1/2)  length  width 
height. Tumors, regional lymph nodes, and lungs were also
analyzed by histology.
In Vivo and Ex Vivo Bioimaging, Histological,
and IHC Analysis of Orthotopic Thyroid Tumors
The computed tomography, multispectral fluorescence scan-
ner (CRi Maestro 500, CRi Inc., Woburn, MA), histopathol-
ogy, and IHC are described in the supplemental online data.
Scoring for Metastases
Metastases were counted and averaged at 40 using hema-
toxylin and eosin–stained, formalin-fixed sections of
lymph nodes and lungs.
Mass Spectrometric Genotyping
Genomic DNA from thyroid cancer lines was purified and
subjected to mass spectrometric genotyping as described
previously [22]. The RET/PTC-1 analysis was performed
according to Puxeddu et al. [23].
Statistical Analysis
Statistical analyses were performed using Microsoft Excel
with Student’s t-test and the 
2 test. p-values .05 were
considered significant (*p  .05, **p  .01, ***p  .001).
The data represent the average  standard deviation or, in
thecaseofreal-timeRT-PCRormiceexperiments,mean
standard error of the mean.
RESULTS
PLX4720 Downregulates ERK-1/ERK-2
Phosphorylation and Inhibits Migration and
Invasion in 8505c Cells Harboring B-Raf
V600E
For our in vitro studies, we used 8505c, an aggressive and
authentic [24] human thyroid carcinoma cell line that we
have shown to be tumorigenic and metastatic in vivo [21]
and to harbor the V600E mutation and TP53 R248G muta-
tion (by mass spectrometric genotyping) (Fig. 1A); 8505c
cells were found to be negative for other mutations (e.g.,
H-, N-, and K-RAS mutations, etc.). Treatment with 1
M PLX4720 resulted in a 90% reduction in phospho-
ERK-1/ERK-2 protein levels after 1 hour (Fig. 1B) with
no significant difference in cell proliferation (BrdU up-
take) even after 72 hours (control versus PLX4720 treat-
ment, 22.6%  3.3% versus 18.4%  1.4%; p  0.1)
(Fig. 2A, 2B, 2D), whereas treating 8505c cells with 10
M PLX4720 for 1 hour or 72 hours reduced phospho-
ERK-1/ERK-2 (Fig. 1B, 1C), reduced BrdU uptake
(19.8%  0.8% versus 3.7%  1.2% in control versus
298 PLX4720 and Preclinical Thyroid Cancer ModelsPLX4720, respectively; p  .001), reduced the S-phase
cell fraction (Fig. 2A, 2B), and caused G1 arrest (38.9%
 1.8% versus 56.4%  1.9% in control versus
PLX4720, respectively; p  .001) (Fig. 2D). PLX4720
treatment (1 Mo r1 0M) did not lead to apoptosis (ab-
sence of sub-G1 cell population) according to the flow
cytometric analysis (Fig. 2D).
Recently, it was demonstrated that PLX4720 induces
activationofC-Raf[25].WeanalyzedC-Rafproteinlev-
els and did not find a significant difference after 1 hour
Figure 1. p-ERK-1/ERK-2 expression in thyroid cancer cells. (A): B-Raf
V600E mutation in 8505c cells; TPC-1 cells have wt
B-Raf and harbor the PIK3CA H1047R mutation and RET/PTC-1 translocation. (B): One hour of 1 M PLX4720 treatment re-
sulted in lower p-ERK-1/ERK-2 levels (by Western blotting) in 8505c cells, but higher levels in TPC-1 cells. p-ERK-1/ERK-2
levels were lower in 8505c cells and TPC-1 cells with 10 M PLX4720. (C): 72 hours of PLX4720 treatment resulted in lower
p-ERK-1/ERK-2 levels in 8505c cells and higher levels in TPC-1 cells.
Abbreviations: DMSO, dimethyl sulfoxide; ERK, extracellular signal–related kinase; p, phosphorylated; wt, wild-type.
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plemental online Fig. 1A). Additionally, the Raf–ERK
pathway can synergize with phosphoinositide 3-kinase
(PI3K)/Akt–mediated signaling on specific biochemical
effectors [26] and we wanted to see whether phospho-
ERK-1/ERK-2downregulationbyPLX4720couldaffect
downstream targets such as Akt phosphorylation levels.
We found no significant difference in phospho-Akt
ser473 protein levels in 8505c cells after 1 hour with
PLX4720 treatment, compared with the control (supple-
mental online Fig. 1A).
We have previously shown an important role for
B-Raf
V600E in mediating migration and invasion of 8505c
into Matrigel [19]. One micromolar PLX4720 reduced mi-
grationfrom71.31.5cells/fieldto351migratedcells/
field, and 10 M PLX4720 further reduced migration to
Figure 2. PLX4720 inhibits proliferation in thyroid cancer cells. (A–C): 1 M PLX4720 reduced BrdU incorporation in TPC-1
cells (*p  .01); 10 M PLX4720 reduced BrdU uptake in 8505c and TPC-1 cells (***p  .001). (D): 1 M PLX4720 signifi-
cantly reduced S-phase (*p  .01) and caused G1 phase arrest (**p  .01) in TPC-1 cells and 10 M PLX4720 reduced S-phase
(***p  .001) and caused G1 phase arrest (**p  .001) in both TPC-1 and 8505c cells.
Abbreviations: BrdU, bromodeoxyuridine; DMSO, dimethyl sulfoxide; wt, wild-type.
300 PLX4720 and Preclinical Thyroid Cancer Models26  6.7 cells/field (p  .001) (Fig. 3A, 3B). Invasion was
also approximately twofold lower using 1 M PLX4720
(27.2  6.7 cells/field versus 52.7  2.1 cells/field; p 
.001) and fourfold lower using 10 M (13.6  4.0 cells/
field versus 59.5  8.8 cells/field; p  .001) (Fig. 3A, 3B).
PLX4720 CAUSES SIGNIFICANT REDUCTION IN
CELL PROLIFERATION AND MIGRATION IN
TPC-1 CELLS
TPC-1 is another authentic human thyroid carcinoma cell
line [24] with a known RET/PTC-1 translocation [27] that
we have confirmed to have wt B-Raf and found to harbor a
PIK3CA H1047R mutation (Fig. 1A) (by mass spectromet-
ric genotyping); TPC-1 cells were found to be negative for
other mutations (e.g., H-, N-, and K-RAS mutations, etc.).
Though TPC-1 cells grew rapidly in vitro, they showed
verylowinvivotumorigenicity,withameantumorsize1
mm
3 after 60 days post-orthotopic injection (supplemental
online Fig. 2).
Paradoxically, in TPC-1 cells, treatment with 1 M
PLX4720 for 1 hour resulted in higher phospho-ERK-1/
ERK-2 protein levels (by approximately 80%); however, 1
hour of treatment with 10 M PLX4720 reduced phospho-
ERK-1/ERK-2 by about 45% (Fig. 1B). Seventy-two hours
oftreatmentwith1Mor10MPLX4720resultedinper-
sistently elevated levels of phospho-ERK-1/ERK-2 protein
(95% and 400%, respectively) (Fig. 1B, 1C). Both 1 M
and 10 M PLX4720 caused lower cell proliferation as
measured by BrdU uptake (27.9%  6.0% in controls ver-
sus 12.9%  2.9% with 1 M PLX4720; p  .01 and
36.7%  2.2% with control treatment versus 14.9% 
0.2% with 10 M PLX4720; p  .001) (Fig. 2A–2C). Nei-
ther 1 M nor 10 M PLX4720 lead to apoptosis (absence
ofsub-G1cellpopulation)inTPC-1cellsevaluatedbyflow
cytometric analysis (Fig. 2D).
In addition, we found that only 10 M PLX4720 re-
duced the migration of TPC-1 cells after 72 hours of treat-
ment. Migration was about 1.6-fold lower (42.6  16.7
cells/field versus 78.6  6.8 cells/field) with 10 M
PLX4720 (Fig. 3A). No significant differences were found
for invasion with either 1 Mo r1 0M PLX4720 (Fig.
3B). There was no significant difference in the levels of
phospho-Akt ser473 (supplemental online Fig. 1A) or C-
Raf with PLX4720, compared with controls (supplemental
online Fig. 1B).
PLX4720 INHIBITS CELL PROLIFERATION,
MIGRATION, AND INVASION IN NT CELLS WITH
B-RAF
V600E OVEREXPRESSION
To understand the role of B-Raf
V600E in thyroid cell migra-
tion and invasion in the heterozygous setting, we stably
overexpressed B-Raf
V600E in NT cells (passage 0). These
NT cells have two wt B-Raf alleles, are positive for cyto-
keratin, and are negative for desmin, indicating epithelial
origin. They are also positive for the following thyroid-
specific markers: TSH receptor, thyroperoxidase (TPO),
thyroid transcription factor (TTF)-1, and paired box gene 8
(PAX-8) (supplemental online Fig. 3). Stably overexpress-
ing B-Raf
V600E in NT cells (B-Raf
V600E–NT cells) resulted
in greater B-Raf mRNA and protein expression: 4.24  0.1
copiesinemptyvectorNTcellsversus52.46.1copiesin
B-Raf
V600E–NT cells (p  .001) (Fig. 3C). Stable
B-Raf
V600E overexpression (detected by anti-tag-c-myc-B-
Raf
V600Eantibody)intheseotherwisenormalearly-passage
thyroid follicular cells, even in the presence of a wt B-Raf
allele (heterozygous wt B-Raf/B-Raf
V600E), resulted in pro-
foundfunctionalchangesincluding:(a)significantlyhigher
phospho-ERK-1/ERK-2 protein levels than in NT cells
transduced with the empty vector (Fig. 3C), (b) greater cell
migration (35.2  5.2 cells/field in overexpressed
B-Raf
V600E NT cells versus 6.7  2.7 cells/field in the con-
trol; p  .001) (Fig. 3D), and (c) greater invasion (60.2 
8.0 cells/field in overexpressed B-Raf
V600E cells versus
12.2  2.0 cells/field in the control; p  .001) (Fig. 3D).
PLX4720 treatment (1 M) of B-Raf
V600E–NT cells re-
sulted in lower migration—21.2  7.4 cells/field versus
35.2  5.2 cells/field in cells treated with the vehicle (p 
.05)—and 10 M was even more effective at reducing mi-
gration—10.7  3.4 cells/field in cells treated with
PLX4720 versus 37  12.6 cells/field in cells treated with
the vehicle; p  .01 (Fig. 3D). One micromolar PLX4720
also resulted in lower B-Raf
V600E–NT cell invasion—21 
0.8 cells/field versus 60.2  8.0 cells/field in cells treated
with the vehicle (p  .001). Ten micromolar PLX4720 was
even more effective at reducing invasion—9.5  1.9 cells/
field in cells treated with PLX4720 versus 59  11.1 cells/
field in cells treated with the vehicle; p  .001 (Fig. 3D).
B-Raf
V600E–NTcellstreatedwith10MPLX4720(butnot
with 1 M) showed significantly lower cell proliferation—
17.3%1.8%incellstreatedwith10MPLX4720versus
27.3%  0.7% in cells treated with vehicle; p  .01 (sup-
plemental online Fig. 4). No significant differences in cell
proliferation (supplemental online Fig. 4), migration, or in-
vasion were found in NT cells transduced with the empty
vectortreatedwithPLX4720(either1Mor10M),com-
pared with the vehicle (Fig. 3D).
PLX4720 Inhibits Tumor Aggressiveness In Vivo
Sixteen animals had 8505c cells tagged with GFP orthoto-
picallyimplantedintotherightthyroidlobe.Oneweekafter
tumor implantation, mice were randomized and treatment
wasinitiated;eightanimalsweretreatedwithPLX4720(30
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ceived control gavage. Control mice began to lose weight
anddevelopdramaticsignsofcachexiaatapproximately28
days. By 35 days, all controls showed evidence of cachexia
Figure 3. Migration and invasion assays with PLX4720 treatment in thyroid cancer cell models. Treatment with 1 M (A) or 10
M (B) PLX4720 reduced migration and invasion in 8505c cells (***p  .001). (B): Migration of TPC-1 cells was lower with 10
M PLX4720 (***p  .001). (C): PLX4720 inhibited p-ERK-1/ERK-2 in B-Raf
V600E-overexpressed primary human NT follic-
ular cells, compared with NT cells transduced with the EV. (D): Migration and invasion of NT cells with B-Raf
V600E overexpres-
sion were inhibited by PLX4720 (***p  .001).
Abbreviations: ERK, extracellular signal–related kinase; EV, empty vector; NT, normal thyroid; p, phosphorylated; wt, wild-type.
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4.2 g  1.1 g (23% of baseline  6%) (p  .001) (Fig. 4).
However, the mice in the PLX4720 treatment group main-
tained their weight and showed no signs of cachexia (Fig.
4). Five weeks post–tumor implantation, all animals were
sacrificed and there was a dramatically (97%) lower tumor
volume in PLX4720-treated animals than in controls (1.9
mm
3 versus 72  18 mm
3; p  .001) (Fig. 4). These results
confirmtheinvivoeffectsofPLX4720withthyroidcancer
cellsthatharborB-Raf
V600E[19].Here,forthefirsttime,we
show detailed histological and IHC analyses performed on
B-Raf
V600E-positive orthotopic thyroid carcinomas treated
with PLX4720 or vehicle (control). The control tumors
grewcircumferentiallyaroundthetracheawithextrathyroi-
dal extension, and these tumors demonstrated histologic
features of aggressiveness such as tracheal invasion, pleo-
morphism, and numerous mitotic figures (Fig. 5A1–5A4).
The PLX4720-treated mice, however, had small and dis-
crete tumor foci with minimal evidence of local invasion
grossly or histologically (Fig. 5A5–5A8). Additionally,
the proliferative index (Ki67 nuclear expression) in the
PLX4720-treated orthotopic tumors was significantly
lower than in the control (p  .01) (Fig. 4).
None of the mice showed gross evidence of lung metas-
tasis, but on fluorescence microscopy there were numerous
evident metastases in control mice lungs with a dramati-
cally lower number of metastases in treated animals (99%
lower) (Fig. 4B). Histologic evaluation showed that eight
mice from the control group had multiple metastatic foci
(average,15.72.4)(Fig.5B1,5B2),whereasnohistolog-
ical evidence of lung metastasis could be found in the lungs
of the PLX4720-treated mice (average, 0) (p  .001) (Fig.
5B5, 5B6). Lymph node metastases are not frequently seen
in our model of thyroid cancer (50% of cases) (Fig. 5B3,
5B4) and no lymph node metastases were seen in the
PLX4720-treated group (Fig. 5B7, 5B8).
Tumors from mice receiving PLX4720 showed upregu-
lation of thyroid-specific cell differentiation markers (i.e.,
TTF-1 and PAX-8) at the protein level by IHC (Fig. 5C).
IHC staining showed moderate immunoexpression of
TTF-1 (diffuse nuclear localization) in PLX4720-treated
8505c orthotopic thyroid tumors, compared with weaker
immunoexpression in untreated 8505c orthotopic thyroid
tumors (control). Similarly, PAX-8 IHC showed weak cy-
toplasmic localization staining and absence in the nuclei in
control orthotopic carcinomas, whereas the PLX4720-
treated orthotopic carcinomas showed greater focal nuclear
positivity (with normal thyroid follicular cells that were
strongly positive in the nuclei) (Fig. 5C). Other thyroid cell
differentiation markers, such as TPO, thyroglobulin (Tg),
TSH receptor, and human sodium–iodide symporter
(hNIS), showed neither immunoexpression in the controls
nor upregulation after 3 weeks of PLX4720 treatment in
this model.
Additionally, given that PLX4720 caused a paradoxical
increase in phospho-ERK-1/ERK-2 in vitro in wt B-Raf
thyroid cancer cells (TPC-1) and wt B-Raf NT cells, we
tested in vivo phospho-ERK-1/ERK-2 levels in mouse tis-
sues that express wt B-Raf after treatment with PLX4720.
We found no significant difference in phospho-ERK-1/
ERK-2 levels in tissue protein extracts from muscles of
SCID mice, compared with control animals, 35 days post–
tumor injection (supplemental online Fig. 1B).
PLX4720 DOWNREGULATES GENES INVOLVED IN
CELL PROLIFERATION,M IGRATION, AND INVASION
Inordertoidentifygenesthataredownstreamtargetsofthe
B-Raf
V600E signaling cascade, we quantified absolute
mRNAexpressioninvitroinboth8505candTPC-1human
thyroid cancer cells following treatment with PLX4720 or
vehicle.WeanalyzedmRNAcopynumberofearlyandlate
gene expression with 1 Mo r1 0M of PLX4720 for
many genes crucial to the control of cell proliferation,
migration, and invasion mechanisms (supplemental on-
line Table 1).
In 8505c cells, we found that only high doses (10 M)
of PLX4720 led to significantly lower mRNA expression
levels at 72 hours in the following: cyclin D1 (CCND1)
(12.1  0.4 copies), thrombospondin-1 (TSP-1) (12.6 
1.2 copies), and integrin 6 (ITGA6) (2.9  0.33 copies),
comparedwithcontrols(38.11.7copies,45.61.3cop-
ies, and 9.7  0.4 copies, respectively; p  .05) (Fig. 6).
In contrast, we found that the TSP-1 copy number was
lower in 8505c cells after 24 hours of treatment with
PLX4720atboththe1M(32.40.58copies)and10M
(11.4  0.9 copies) levels, compared with controls
(67.84  2.27 copies and 48.05  0.9 copies, respectively;
p  .05) (Fig. 6). In addition, the TSP-1 copy number was
lower in TPC-1 cells treated with PLX4720 (at both the 1
M and 10 M levels) than in controls (Fig. 6).
In 8505c cells, we found that both 1 M and 10 M
PLX4720 resulted in a higher mRNA expression level of
the thyroid follicular cell differentiation marker TTF-1 at
72 hours of treatment (9.5 copies and 9.5  0.4 copies, re-
spectively) than in controls (5.1  0.2 copies and 5.1  0.3
copies, respectively; p  .05) (Fig. 6). The TTF-1 copy
number was greater in 8505c cells after 24 hours of
PLX4720 treatment with both 1 M PLX4720 (25.5  1.2
copies) and 10 M PLX4720 (14.7  0.3 copies) than in
controls (19.6  0.9 copies and 11.4  0.5 copies, respec-
tively; p  .05) (Fig. 6). In contrast, PAX-8 showed low
mRNA basal levels (1 copy number). Furthermore, TPO,
303 Nucera, Nehs, Nagarkatti et al.
www.TheOncologist.comTg, TSH receptor, and hNIS showed very low mRNA copy
numbers (0.2 copy number) and no upregulation with
PLX4720treatmentin8505ccells;thisresultwasalsocon-
firmed by IHC, which showed undetectable protein levels
both in controls and in PLX4720-treated orthotopic thyroid
carcinomas.
Figure4. Tumorgrowthandlungmetastasisinanorthotopicmousemodelofhumananaplasticthyroidcancer.(A):Threeweeks
ofPLX4720treatmentresultedinlowerorthotopictumorgrowththanincontrols(***p.001).Grossphoto(B1)and3DCTscan
(B3) show a large B-Raf
V600E 8505c orthotopic thyroid carcinoma (control, arrow) and a dramatically smaller (B2 and B4) or-
thotopic tumor size with PLX4720 treatment (gross photo, arrow; 3D CT scans, asterisk) in SCID mice. (B5): Lung metastases
(arrows)byGFPincontrolB-Raf
V600E8505corthotopicthyroidcarcinomaSCIDmice.(B6):Significantlyfewerlungmetastases
inPLX4720-treatedmice.(C)Controlmicebecamecachecticbetween28and35daysandlostanaverageof23%oftheirbaseline
weight,whereasPLX4720-treatedmicemaintainedtheirbaselineweight(***p.001).(D):Lowproliferativeindex(percentage
of Ki-67 protein nuclear expression) in PLX4720-treated B-Raf
V600E 8505c orthotopic tumors, compared with controls (**p 
.01).
Abbreviations: 3D, three-dimensional; CT, computed tomography; DMSO, dimethyl sulfoxide; GFP, green fluorescent pro-
tein; SCID, severe combined immunodeficient.
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The typical treatment regimen of surgical excision, levo-
thyroxine suppression, and radioactive iodine is successful
in close to 90% of patients with differentiated thyroid can-
cer. However, for the group of patients who fail to respond
to this treatment paradigm or initially present with aggres-
sive and refractory thyroid carcinoma, survival rates are
very low [28]. There are very few clinical trials for thyroid
cancer[29],withapartialresponserateof30%insomesin-
gle-agent studies [30]. The response rate for ATC is much
lower, and consequently, 50% of thyroid cancer deaths
are attributed to ATC [1].
By identifying the “driving events” behind thyroid can-
cer proliferation and migration/invasion, targeted molecu-
Figure5. PLX4720inhibitsB-Raf
V600E-positivethyroidtumoraggressivenessinvivo.(A):ControlmicewithB-Raf
V600E8505c
orthotopictumors(H&Estain)werelarge(A1)andshowedextrathyroidalextensionintothetrachea(A1,A2)andskeletalmuscle
(A3) with atypical mitoses (A4, arrow); PLX4720-treated tumors (H&E stain) were small and discrete (A5–A7) (arrows) and
largely confined to the thyroid bed, with atypical pyknotic nuclei (A8). (B): Control SCID mice (H&E stain) had metastatic foci
of carcinoma to the lung interstitium (arrows, B1, B2) as well as a paratracheal lymph node (asterisk, (B3); higher power, arrow
(B4)); PLX4720-treated mice had no evidence of metastasis to the lung (B5, B6) or lymph nodes (B7, B8). (C): PLX4720-treated
tumors had greater nuclear staining for TTF-1 and PAX-8 (right) than untreated control mice (left).
Abbreviations: H&E, hematoxylin and eosin; SCID, severe combined immunodeficient; TTF-1, thyroid transcription factor.
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Current molecular strategies involve interrupting intracel-
lular signal transduction pathways at specific targets, such
as B-Raf, Ras, MEK, PI3K, RET, cMet, and epidermal
growth factor [31]. Given that B-Raf
V600E is the most prev-
alent mutation implicated in the initiation and aggressive-
nessofPTC,andpossiblyintheprogressionofPTCtoATC
[31, 32], targeting this mutation holds great potential for
Figure6. GeneexpressionwithPLX4720treatment.Quantitativereal-timeRT-PCRshowsmRNAcopynumberofCCND1(A),
TSP-1 (B), ITGA6 (C), and TTF-1 (D) mRNA in 8505c and TPC-1 cells after 24 hours or 72 hours of treatment with PLX4720
(either 1 Mo r1 0M).
Abbreviations: CCND1, cyclin D1; ITGA6, integrin 6; RT-PCR, reverse transcriptase polymerase chain reaction; TSP-1,
thrombospondin-1; TTF-1, thyroid transcription factor; wt, wild-type.
306 PLX4720 and Preclinical Thyroid Cancer Modelsnovel therapies. We chose to study this both in vitro and in
vivo using PLX4720, a potent and selective B-Raf
V600E in-
hibitor. In one previous report, in vitro treatment of
B-Raf
V600E-positive thyroid cancer cell lines with
PLX4720 (50% inhibitory concentration in the range of
78–113 nM) showed cell cycle arrest, whereas RET/PTC-1
and Ras mutated thyroid cancer cell lines were resistant to
inhibition even at 500 nM [27].
In contrast, we found that only higher doses (both 1 M
and 10 M) of PLX4720 caused cell cycle arrest and inhib-
ited tumor cell migration and invasion in 8505c cells (B-
Raf
V600E). Interestingly, by overexpressing B-Raf
V600E in
NT cells, we were able to create a heterozygous model that
genetically reproduces human thyroid cancers that have
both a B-Raf
V600E allele and a wt B-Raf allele. With this
overexpression of B-Raf
V600E, the ability of NT cells to in-
vade and migrate was much greater than in controls. The
gain of these functions was effectively inhibited by 10 M
PLX4720, suggesting a strong role for B-Raf
V600E in thy-
roid cancer progression. Therefore, this is the first in vitro
translationaldemonstrationthatPLX4720mightbeauseful
compoundinclinicaltrialsforpatientswiththyroidcancers
harboring the B-Raf
V600E mutation.
Recently, it was shown that PLX4720 could have unex-
pected effects in some cell contexts (e.g., presence of wt B-
Raf and mutated Ras) as a result of ERK-1/ERK-2
activation [25, 33, 34]. However, in our study, PLX4720
treatment of NT cells (wt B-Raf/wt B-Raf) transduced with
empty vector did not result in greater proliferation, migra-
tion, or invasion despite a higher level of phospho-ERK-1/
ERK-2. Somewhat unexpectedly, cell proliferation and
migration were also inhibited in TPC-1 cells (RET/PTC-1
translocation, PIK3CA H1047R mutation, and wt B-Raf).
These results indicate that certain wt B-Raf thyroid tumors
(perhaps those that harbor RET/PTC-1 and/or PIK3CA
H1047R)mightbesomewhatresponsivetoPLX4720treat-
ment as well. Further preclinical validation is needed to un-
derstand this phenomenon prior to human testing.
PLX4720 treatment downregulated genes involved in
cellproliferation,suchasCCND1,andcertaingenesknown
tobeimportantinmigration,invasion,andmetastasis,such
as TSP-1 and ITGA6 [35]. We have previously shown that
knockdown of TSP-1 decreases phospho-ERK-1/ERK-2
levelsandreducesthyroidcancerprogression[19],perhaps
through binding of the N-terminal domain of TSP-1 to in-
tegrins such as 31o r61 [36, 37]. TSP-1 is known to
be intimately involved in the regulation of cellular prolifer-
ation by affecting early response genes [38], and our data
are consistent with those results [19].
Our in vitro studies show higher phospho-ERK-1/
ERK-2 levels when TPC-1 cells are treated with PLX4720.
Recent findings by Hatzivassiliou et al. [34] showed that
ATP-competitive Raf inhibitors, including PLX4720, have
opposing roles as inhibitors and activators of ERK-1/
ERK-2 phosphorylation depending on the cellular and ge-
notypic context. Furthermore, other authors recently reported
that inhibition of wt B-Raf by PLX4720 in Ras mutant (e.g.,
N-Ras) human cancer cells (i.e., melanoma cells) leads to
MEK–ERK-1/ERK-2 hyperactivation through C-Raf [25].
These aforementioned studies [25, 33, 34, 39] and others [40]
highlight the importance of individualized genomic profiling
to guide patient selection for inclusion in targeted therapy tri-
als.WealsofoundthatPLX4720treatmentinvitroandinvivo
in8505ccellsupregulatedimportantthyroid-relatedtranscrip-
tion factors, such as TTF-1 and PAX-8, that have been widely
described as markers of thyroid follicular cell differentiation,
thussuggestingthatB-Raf
V600Emightplayabiologicalrolein
thyroid follicular cell dedifferentiation.
In vivo, we demonstrated a dramatic reduction in tumor
aggressiveness in our orthotopic mouse model of ATC.
PLX4720treatmentreducedtumorvolumeby97%andvir-
tuallyeliminatedmetastaticspreadtothelungs.Thoughthe
ATC cell line 8505c also harbors a TP53 mutation [41], the
selectiveinhibitionofB-Raf
V600Ewassufficienttodramat-
ically reduce tumor volume, extrathyroidal extension, and
metastasis without any obvious toxicity. Both in vitro and in
vivoresultspointtothepotentialtherapeuticutilityofthisdrug
in patients with advanced B-Raf
V600E thyroid cancers.
In conclusion, our study shows that inhibition of
B-Raf
V600E with the novel agent PLX4720 results in dra-
matic changes in cell proliferation, migration, and invasion
in vitro, and early intervention with this drug results in
marked inhibition of tumor aggressiveness in an in vivo
modelofATCharboringB-Raf
V600E.Ourinvitromodelus-
ing primary human NT follicular cells (heterozygous wt
B-Raf/B-Raf
V600E) recapitulates the genetic status of this
mutation in human thyroid cancer, and is the first preclini-
cal model to show that PLX4720 inhibits cell proliferation,
migration, and invasion in a B-Raf
V600E heterozygous
model. PLX4720 might be an effective therapy for appro-
priately selected patients with metastatic or refractory thy-
roid cancers that harbor the B-Raf
V600E mutation.
SUMMARY AND CLINICAL RELEVANCE
Despite considerable enthusiasm about targeted therapies
and understanding the underlying reasons why the
B-Raf
V600E mutation may lead to more aggressive clinical
behavior in some patients with thyroid cancer, there have
not been many studies on the inhibition of B-Raf
V600E. Our
study shows that inhibition of B-Raf
V600E with the novel
agent PLX4720 can decrease cell proliferation, migration,
and invasion in thyroid cancer cell lines and markedly in-
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model of human ATC harboring B-Raf
V600E. Additionally,
ourinvitromodelusingprimaryhumanNTcells(heterozy-
gous wt B-Raf/B-Raf
V600E) recapitulates the genetic status
ofthismutationinhumanthyroidcancer;itisthefirsttrans-
lationaldemonstrationtoshowthatPLX4720iseffectivein
a B-Raf
V600E heterozygous model. Our results suggest that
PLX4720 might be an effective therapy in clinical trials for
the treatment of patients with B-Raf
V600E-positive thyroid
cancers that are refractory to conventional therapy.
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